2019
Clinical Outcomes and Complications of Peroneal Tendon Sheath Ultrasound-Guided Corticosteroid Injection
Fram BR, Rogero R, Fuchs D, Shakked RJ, Raikin SM, Pedowitz DI. Clinical Outcomes and Complications of Peroneal Tendon Sheath Ultrasound-Guided Corticosteroid Injection. Foot & Ankle International 2019, 40: 888-894. PMID: 31068007, DOI: 10.1177/1071100719847629.Peer-Reviewed Original ResearchConceptsCorticosteroid injectionBody mass indexMagnetic resonance imagingPain reliefPrior surgeryPeroneal tendonsClinical outcomesCompensation statusPeroneal tendinopathyNonsteroidal anti-inflammatory drugsWorkers' compensation statusDuration of symptomsPeroneal tendon tearsMedical record dataAnti-inflammatory drugsNumber of injectionsNonoperative modalitiesNerve irritationNonoperative treatmentUnderlying diagnosisNonoperative managementPatient ageCase seriesIntraoperative findingsMass index
2014
Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET
Lukens JN, Nasta SD, Fram B, Glatstein E, Plastaras JP. Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET. American Journal Of Clinical Oncology 2014, 37: 35-40. PMID: 22992623, DOI: 10.1097/coc.0b013e31826106c9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm GradingNeoplasm StagingPositron-Emission TomographyRadiotherapy, Computer-AssistedRetrospective StudiesRituximabTomography, X-Ray ComputedTreatment OutcomeConceptsInvolved field radiation therapyProgression-free survivalNon-Hodgkin lymphomaLow-grade non-Hodgkin lymphomaPositron emission tomographyIndolent non-Hodgkin lymphomaComputed tomographyWeekly dosesRadiation therapyFavorable progression-free survivalImproved progression-free survivalOverall progression-free survivalReceipt of rituximabRituximab-treated patientsUse of rituximabPFS ratesMore patientsProspective studyHistorical controlsRetrospective analysisRituximabPatientsStage IIEmission tomographySignificant differences